Hypericin

Research use only, not for human use.

Hypericin inhibits RANKL-mediated osteoclastogenesis via affecting ERK signalling in vitro and suppresses wear particle-induced osteolysis in vivo.

Hypericin, also known as SGX301, is a novel, first-in-class photodynamic therapy using a potent photosensitizer, synthetic hypericin, that is topically applied and activated by safe visible fluorescent light. This treatment avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging chemotherapeutic drugs and other photodynamic therapies that are dependent on ultraviolet A (UVA) light exposure.

Cell Viability Assay Cell Line:Fibroblasts (Fb), melanocytes (Mc), and keratinocytes (Kc)Concentration:0.25 μM; 0.5 μM; 1 μM; 2 μM; 3 μM; 4 μM Incubation Time:24 hours Result:Showed the LD50 for Fb and Mc at 1.75 μM and 3.5 μM, respectively, and for Kc at a greater dose than 4 μM.Apoptosis Analysis Cell Line:Fibroblasts (Fb), melanocytes (Mc), and keratinocytes (Kc)Concentration:3 μM Incubation Time:24 hours Result:Showed a significant (p<0.001) early apoptotic Fb population (64%), and a smaller, significant (p<0.05) early apoptotic Mc population (20%).

Animal Model:18-20 week-old female BALB/c mice injected withCT26 carcinomas Dosage:10 mg/kg Administration:Intravenous injection; 10 mg/kg; once Result:Showed a four times delayed tumor growth compared to the control groups.

SGX301 | SGX-301 | NSC 622946 | hypericin

Microbiology/Virology

Antibiotic

antibacterial|antiviral

Others-Field

——

548-04-9

504.45

C30H16O8

>98% (HPLC)

DMSO : 6.2 mg/mL 12.29 mM

CC1=CC(=C2C3=C1C4=C5C(=C(C=C4C)O)C(=O)C6=C(C=C(C7=C6C5=C3C8=C7C(=CC(=C8C2=O)O)O)O)O)O

1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro(1,10,9,8-opqra)perylene-7,14-dione

(-20℃)

With Ice Pack

≥ 2 years